149 related articles for article (PubMed ID: 12625415)
1. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
Hirose T; Mizuno R; Yoshimoto T
Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
[TBL] [Abstract][Full Text] [Related]
2. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
4. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
[TBL] [Abstract][Full Text] [Related]
5. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N
Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606
[TBL] [Abstract][Full Text] [Related]
6. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
[TBL] [Abstract][Full Text] [Related]
7. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
8. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
9. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Miura K; Kitahara Y; Yamagishi S
Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
[TBL] [Abstract][Full Text] [Related]
13. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
16. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
[TBL] [Abstract][Full Text] [Related]
17. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
18. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
19. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
de Souza CJ; Gagen K; Chen W; Dragonas N
Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
[TBL] [Abstract][Full Text] [Related]
20. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
